Hypertensive heart disease and noninsulin-dependent diabetes mellitus: modern strategies in antihypertensive therapy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Hypertension (HTN) and noninsulin-dependent diabetes mellitus (NIDDM) are two non-communicable pandemic of the late 20th century and early 21st century. Despite the active prophylaxis measures performed by the State, there is a tendency to increase of HTN in Russia. Incidence rate of hypertension is depending of age and increases in patients of elderly age (80%). According to the International Diabetes Federation, 10% of people in Russia suffer NIDDM of different genesis. The authors covered the topical issues of modern strategies in antihypertensive therapy in patients with NIDDM and HTN according to large randomized trials. The authors analyzed the possibilities of conventional and modern therapies of hypertension, organoprotection, metabolic neutrality and impact on prognosis in patients with NIDDM. It is underlined that the renin-angiotensin-aldosterone system is a part of the cardiovascular continuum and links various risk factors, like end-stage of cardiovascular disease and chronic renal disease. Monitoring of arterial blood pressure is crucial for patients with essential hypertension and NIDDM. Pharmacological blockade of the renin-angiotensin-aldosterone system is the most desirable method of treatment of hypertension and noninsulin-dependent diabetes mellitus. This method reduces the risk of cardiovascular complications.

Full Text

Restricted Access

References

  1. Барсуков А.В., Багаева З.В. Особенности состояния липидного и углеводного обмена у пациентов с эссенциальной гипертензией и избыточной массой тела в зависимости от типа гипертрофии левого желудочка // Артериальная гипертензия. — 2009. — Т. 15 (Приложение № 2). — С. 13—14.
  2. Бубнова М.Г. Лечение артериальной гипертонии в клинической практике: от общих принципов к конкретному пациенту // Трудный пациент. — 2006. — Т. 4, № 8. — С. 5—13.
  3. Шальнова С.А. Эпидемиология артериальной гипертензии в России: портрет больного // Артериальная гипертензия (Клінічний семінар). - 2008. - Т. 2, № 2. - С. 5-9.
  4. Шустов С.Б., Баранов В.Л., Халимов Ю.Ш., Потин В.В. Эндокринология в таблицах и схемах. - М.: МИА, 2009. - 656 с.
  5. ACCORD Study Group, Cushman W.C., Evans G.W., Byington R.P. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus // New Engl. J. Med. - 2010. - Vol. 362, N 17. -P. 1575-1585.
  6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT) // JAMA. - 2002. - Vol. 288. -P. 2981-2997.
  7. Bakris G.L., Sarafidis H.A., Weir V.R. et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial // Lancet. - 2010. - Vol. 375. - P. 1173-1181.
  8. Brenner B.M., Cooper M.E., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy // New. Engl. J. Med. — 2001. - Vol. 345, N 12. - P. 861-869.
  9. Curb J.D., Pressel S.L., Cutler J.A. et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease in older diabetic patients with isolated systolic hypertension // JAMA. -1996. - Vol. 276. - P. 1886-1892.
  10. Dahlof B., Sever P., Poulter N.R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial // Lancet. - 2005. - Vol. 366. - P. 895-906.
  11. Du X., Ninomiya T., Abadis E. et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study // Eur. Heart. J. - 2009. -Vol. 30, N 9. - P. 1128-1135.
  12. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial // Lancet. - 1998. -Vol. 351. - P. 1755-1762.
  13. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy // Lancet. - 2000. - Vol. 355. -P. 253-259.
  14. Holman R.R., Paul S.K., Bethel M.A. et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes // New Engl. J. Med. -2008. - Vol. 359, N 15. - P. 1565-1576.
  15. Julius S., Weber M.A., Kjeldsen S.E. et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy // Hypertension. - 2006. - Vol. 48, N 3. - P. 385-391.
  16. Kasanuki H., Hagiwara N., Hosoda S. et al. Angiotensin II receptor blocker-based vs. nonangiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE) // Eur. Heart. J. - 2009. - Vol. 30, N 10. - P. 1203-1212.
  17. Kurtz T.W. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator // Acta Diabetol. - 2005. - Vol. 42 (Suppl. 1). -P. 9-16.
  18. Kurtz T.W., Klein U. Next generation multifunctional angiotensin receptor blockers // Hypertens Res. — 2009. — Vol. 32, N 10. — P. 826-34.
  19. Lam S.K., Owen A. Incident diabetes in clinical trials of antihypertensive drugs // Lancet. - 2007. - Vol. 369, N 9572. - P. 1513-1514.
  20. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // New. Engl. J. Med. - 2001. - Vol. 345, N 12. -P. 851-860.
  21. Lindholm L.H. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis // Lancet. - 2005. - Vol. 366, N 9496. - P. 1545-1553.
  22. Lindholm L.H., Hansson L., Ekbom T. et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. // J. Hypertens. - 2000. - Vol. 18. - P. 1671-1675.
  23. Lindholm L.H., Ibsen H., Dahlof B. et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet. - 2002. - Vol. 359. -P. 1004-1010.
  24. Lindholm L.H., Persson M., Alanpovic P. et al. Metabolic outcome during 1 year in newly detected hypertensives: results in the antihypertensive treatment and lipid profile in the North of Sweden efficacy evaluation (ALPINE-study) // J. Hypertens. - 2003. - Vol. 21. -P. 1563-1574.
  25. MacDonald M.R., Petrie M.C., Varyani F. et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program // Eur. Heart. J. -2008. - Vol. 29, N 11. - P. 1377-1385.
  26. Mancia G., Brown M., Castaigne A. et al. INSIGHT. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT) // Hypertension. - 2003. -Vol. 41. - P. 431-436.
  27. Mancia G., De Backer G., Dominiczak A. et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. - 2007. - Vol. 25, N 6. - P. 11051187.
  28. Mann J. F.E., Schmieder R.E., Dyal L. et al. Effect of Telmisartan on Renal Outcomes. A Randomized Trial // Ann. Intern. Med. - 2009. - Vol. 151, N 1. - P. 1-10.
  29. Niklason A., Hedner T., Niskanen L., Ianke J. Captopril Prevention Project Study Group. Development of diabetes is retarded by ACE inhibition in hypertensive patients — a subanalysis of the Captopril Prevention Project (CAPPP) // J. Hypertens. - 2004. - Vol. 22. - P. 645-652.
  30. The ONTARGET Investigators. Telmisartan. Ramipril, or Both in Patients at High Risk for Vascular Events // New Engl. J. Med. - 2008. - Vol. 358, N 15. - P. 1547-1559.
  31. Papademetriou V., Farsang C., Elmfeldt D. et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE) // J. Am. Coll. Cardiol. - 2004. -Vol. 44, N 6. - P. 1175-1180.
  32. Parving H.H., Lehnert H., Brochner- Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes // New. Engl. J. Med. - 2001. - Vol. 345, N 12. - P. 870-878.
  33. Patel A. ADVANCE Collaborative Group, MacMahon S., Chalmers J., Neal B. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial // Lancet. - 2007. - 370. - P. 829-840.
  34. Pfeffer M.A., Swedberg K., Granger C.B. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall program // Lancet. - 2003. - Vol. 362, N 9386. - P. 759-766.
  35. Ruggenenti P., Fassi A., Ilieva A.P. et al. For the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing Microalbuminuria in Type 2 Diabetes // New. Engl. J. Med. - 2004. - Vol. 351, N 19. -P. 1941-1951.
  36. Ruggenenti P., Fassi A., Llieva A. et al. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial // J. Hypertens. - 2011. - Vol. 29, N 2. - P. 207-216.
  37. Tuomilehto J., Rastenyte D., Birkenhager W.H. et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension // New. Engl. J. Med. - 1999. - Vol. 349. - P. 677-684.
  38. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39 // BMJ. - 1998. - Vol. 317. - P. 713-720.
  39. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type-2 diabetes: UKPDS 38 // BMJ. - 1998. - Vol. 317. - P. 703713.
  40. Weber M.A., Bakris G.L., Jamerson K et al. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes // J. Am. Coll. Cardiol. - 2010. - Vol. 56. -P. 77-85.
  41. Yusuf S., Diener H.C., Sacco R.L. et al. Telmisartan to prevent recurrent stroke and cardiovascular events // New. Engl. J. Med. - 2008. - Vol. 359, N 12. - P. 1225-1237.
  42. Zanchetti A., Ruilope L.M. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? // J. Hypertens. - 2002. - Vol. 20. - P. 2099-2110.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Barsukov A.V., Talantseva M.S.


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 01975 от 30.12.1992.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies